查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612596

比伐卢定市场：按剂型、应用和最终用途 - 2025-2030 年全球预测

Bivalirudin Market by Dosage Form (Injection, Powder), Application (Angioplasty, Heparin-induced Thrombocytopenia, Percutaneous Coronary Intervention), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年比伐卢定市场估值为12.3亿美元，预计2024年将达到13.1亿美元，预计复合年增长率为6.13%，到2030年将达到18.7亿美元。

比伐卢定是一种直接凝血酶抑制剂，对于血栓性疾病的治疗和管理至关重要，特别是对于接受经皮冠状动脉介入治疗 (PCI) 的患者。它对于血栓性疾病的治疗和管理至关重要，特别是对于接受经皮冠状动脉介入治疗（PCI）的患者。它可以作为肝素的替代品，并具有可预测的药物动力学和降低出血风险等优点。心血管疾病的日益普及和世界人口的老化推动了需求。影响比伐卢定市场的关键成长要素包括药物输送系统的进步、对更安全的抗凝血剂选择的认识的提高以及血栓治疗研究的进展。机会包括扩大核准和增加对广泛治疗适应症的使用，特别是在 PCI 治疗呈上升趋势的地区。此外，新兴市场健康意识和医疗保健普及率的持续提高提供了进一步的市场潜力。然而，由于治疗成本上升以及生物相似药和非专利等替代抗凝血剂的竞争，该药物仍存在一些限制。不断变化的监管环境也增加了复杂性，并对市场扩张提出了挑战。研究和创新应着重于改进配方，例如延长保质期和改进递送机制，这可以为门诊和居家医疗铺平道路。此外，进一步探索联合治疗可以增强其临床效用，为个人化医疗铺路。优化供应链策略可以提高成本效率和可近性，尤其是在低收入市场。公司必须紧跟监管变化，并对研发进行策略性投资，以利用未满足的临床需求。製药公司、研究机构和医疗保健提供者之间的持续合作将有助于发挥成长潜力，克服现有的市场障碍，并将比伐卢定有效地整合到更广泛的治疗范式中。

主要市场统计
基准年[2023] 12.3亿美元
预计年份 [2024] 13.1亿美元
预测年份 [2030] 18.7亿美元
复合年增长率（%） 6.13%

市场动态：揭示快速发展的比伐卢定市场的关键市场洞察

供需的动态交互作用正在改变比伐卢定市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 对有效治疗心血管疾病的抗凝血剂的需求增加
    • 消费者在改良药品和药品上的支出增加
  • 市场限制因素
    • 与替代品相比，比伐卢定的特性昂贵
  • 市场机会
    • 即用型比伐卢定製剂的开发进展
    • 政府继续核准新产品
  • 市场问题
    • 与使用比伐卢定相关的风险和併发症

波特的五力：驾驭比伐卢定市场的策略工具

波特的五力架构是了解比伐卢定市场竞争格局的关键工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解比伐卢定市场的外部影响

外部宏观环境因素在塑造比伐卢定市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解比伐卢定市场的竞争格局

比伐卢定市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV 定位矩阵：比伐卢定市场供应商绩效评估

FPNV定位矩阵是评估比伐卢定市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製比伐卢定市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，比伐卢定市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 对治疗心血管疾病的有效抗凝血剂的需求日益增长。
      • 增加消费者在药品和药品改善的支出
    • 抑制因素
      • 与其他选择相比，比伐卢定价格昂贵
    • 机会
      • 即用组合药物的开发
      • 政府正在核准新产品
    • 任务
      • 与使用比伐卢定相关的风险和併发症
  • 市场区隔分析
    • 剂型：比伐卢定在外科手术中常以注射剂的形式使用。
    • 最终用途：比伐卢定在门诊手术中心的新用途
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章比伐卢定市场：按剂型

  • 介绍
  • 注射
  • 粉末

第七章 比伐卢定市场：依应用分类

  • 介绍
  • 血管成形术
  • 肝素诱发的血小板减少性疾病
  • 经皮冠状动脉介入治疗

第 8 章 比伐卢定市场：依最终用途分类

  • 介绍
  • 门诊手术中心
  • 医院/诊所
  • 专科诊所

第九章 北美、南美洲比伐卢定市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太比伐卢定市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲比伐卢定市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Avenacy 推出非专利琴酒注射液，扩大了美国抗凝血药物的选择
    • 远藤国际推出即用型比伐卢定注射液以提高临床效率
    • 远藤国际宣布建立战略合作关係，并分销美国即用型比伐卢定注射液
  • 战略分析和建议

公司名单

  • Apotex Inc.
  • Aurobindo Pharma
  • Avenacy, Inc.
  • Baxter International
  • Cayman Chemical
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Endo International plc
  • Eugia US LLC
  • Fresenius Kabi
  • Meitheal Pharmaceuticals, Inc.
  • Merck KGaA
  • Midas Pharma GmbH
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-7A22CB0E5BB3

The Bivalirudin Market was valued at USD 1.23 billion in 2023, expected to reach USD 1.31 billion in 2024, and is projected to grow at a CAGR of 6.13%, to USD 1.87 billion by 2030.

Bivalirudin, a direct thrombin inhibitor, is critical in the treatment and management of thrombotic conditions, particularly for patients undergoing percutaneous coronary interventions (PCI). Its application serves as an alternative to heparin, showcasing benefits such as predictable pharmacokinetics and reduced bleeding risk. The demand is driven by the growing prevalence of cardiovascular diseases and an aging global population. Key growth factors influencing the bivalirudin market include advancements in drug delivery systems, increasing awareness about safer anticoagulant options, and ongoing research in thrombotic therapies. Opportunities lie in expanding approvals and increasing usage in broader therapeutic indications, particularly in regions with rising PCI procedures. Moreover, the continuous rise in health awareness and access to healthcare in emerging markets provides additional market potential. However, limitations exist due to the high costs of therapy and competitive pressure from alternative anticoagulants, including biosimilars and generics. The evolving regulatory landscape adds another layer of complexity, challenging market expansion. Research and innovation should focus on enhancing bivalirudin formulations for extended shelf life and improved delivery mechanisms, potentially opening more avenues for outpatient and home-based care settings. Further exploration in combination therapies could also augment its clinical utility - paving the way for personalized medicine approaches. Optimizing supply chain strategies can improve cost efficiency and accessibility, particularly in low-income markets, which will be a critical determinant of future market growth. Businesses must stay abreast of regulatory shifts and invest strategically in R&D to leverage unmet clinical needs. Continued collaboration between pharmaceutical companies, research institutions, and healthcare providers will be vital for harnessing potential growth and overcoming existing market barriers, ensuring the effective integration of bivalirudin into more extensive therapeutic paradigms.

KEY MARKET STATISTICS
Base Year [2023] USD 1.23 billion
Estimated Year [2024] USD 1.31 billion
Forecast Year [2030] USD 1.87 billion
CAGR (%) 6.13%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bivalirudin Market

The Bivalirudin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing need for effective anticoagulants to treat cardiovascular disorders
    • Growing consumer expenditure for improved drug and medications
  • Market Restraints
    • Expensive nature of bivalirudin compared to the alternatives
  • Market Opportunities
    • Emerging development of ready-to-use bivalirudin formulations
    • Ongoing government approvals for new products
  • Market Challenges
    • Risks and complexities associated with use of bivalirudin

Porter's Five Forces: A Strategic Tool for Navigating the Bivalirudin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bivalirudin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bivalirudin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bivalirudin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bivalirudin Market

A detailed market share analysis in the Bivalirudin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bivalirudin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bivalirudin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bivalirudin Market

A strategic analysis of the Bivalirudin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bivalirudin Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Aurobindo Pharma, Avenacy, Inc., Baxter International, Cayman Chemical, Cipla Limited, Dr. Reddy's Laboratories, Endo International plc, Eugia US LLC, Fresenius Kabi, Meitheal Pharmaceuticals, Inc., Merck KGaA, Midas Pharma GmbH, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Bivalirudin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Dosage Form, market is studied across Injection and Powder.
  • Based on Application, market is studied across Angioplasty, Heparin-induced Thrombocytopenia, and Percutaneous Coronary Intervention.
  • Based on End-Use, market is studied across Ambulatory Surgical Centers, Hospitals & Clinics, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing need for effective anticoagulants to treat cardiovascular disorders
      • 5.1.1.2. Growing consumer expenditure for improved drug and medications
    • 5.1.2. Restraints
      • 5.1.2.1. Expensive nature of bivalirudin compared to the alternatives
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging development of ready-to-use bivalirudin formulations
      • 5.1.3.2. Ongoing government approvals for new products
    • 5.1.4. Challenges
      • 5.1.4.1. Risks and complexities associated with use of bivalirudin
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Dosage Form: Significant usage of bivalirudin in injectable form during surgical procedures
    • 5.2.2. End-Use: Emerging usage of bivalirudin in ambulatory surgical centers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bivalirudin Market, by Dosage Form

  • 6.1. Introduction
  • 6.2. Injection
  • 6.3. Powder

7. Bivalirudin Market, by Application

  • 7.1. Introduction
  • 7.2. Angioplasty
  • 7.3. Heparin-induced Thrombocytopenia
  • 7.4. Percutaneous Coronary Intervention

8. Bivalirudin Market, by End-Use

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals & Clinics
  • 8.4. Specialty Clinics

9. Americas Bivalirudin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bivalirudin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bivalirudin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Avenacy Introduces Generic Bivalirudin Injection, Expanding Anticoagulant Options in the U.S.
    • 12.3.2. Endo International Launches Ready-to-Use Bivalirudin Injection Enhancing Clinical Efficiency
    • 12.3.3. Endo International Announces Strategic Partnership for U.S. Distribution of Ready-to-Use Bivalirudin Injection
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Apotex Inc.
  • 2. Aurobindo Pharma
  • 3. Avenacy, Inc.
  • 4. Baxter International
  • 5. Cayman Chemical
  • 6. Cipla Limited
  • 7. Dr. Reddy's Laboratories
  • 8. Endo International plc
  • 9. Eugia US LLC
  • 10. Fresenius Kabi
  • 11. Meitheal Pharmaceuticals, Inc.
  • 12. Merck KGaA
  • 13. Midas Pharma GmbH
  • 14. Pfizer Inc.
  • 15. Teva Pharmaceutical Industries Ltd.
  • 16. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. BIVALIRUDIN MARKET RESEARCH PROCESS
  • FIGURE 2. BIVALIRUDIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BIVALIRUDIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BIVALIRUDIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIVALIRUDIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIVALIRUDIN MARKET DYNAMICS
  • TABLE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIVALIRUDIN MARKET SIZE, BY HEPARIN-INDUCED THROMBOCYTOPENIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIVALIRUDIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. BIVALIRUDIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. BIVALIRUDIN MARKET, FPNV POSITIONING MATRIX, 2023